This research was conducted by Hai Fang and team from Peking University and published in the Chinese Journal of Vaccines and Immunization. The study constructed a Decision Tree-Markov model to estimate vaccine costs, economic burden of rotavirus gastroenteritis (RVGE), net present values (NPV), and benefit-cost ratios (BCR) of introducing three different types of RV vaccines into NIP. Results showed that introducing RV vaccine into the NIP was not cost-saving at the current price. Further reduction of the vaccine price would be cost-beneficial for the RV immunization program.
Closing the immunization gap: Overcoming barriers for new vaccine introduction in Southeast and South Asia
This review, conducted by Innovation Lab for Vaccine Delivery Research (VaxLab) from Duke Kunshan University, was published in Vaccine. The study systematically compares the status of new vaccine introduction within national immunization programs across 13 countries in Southeast and South Asia, with a particular focus on differences associated with Gavi funding eligibility. The findings show that countries eligible for Gavi’s middle-income country (MIC) support approach lag behind in introducing key vaccines such as pneumococcal conjugate vaccine (PCV), human papillomavirus (HPV) vaccine, and rotavirus vaccine. Major barriers include underdeveloped evidence-based decision-making processes, limited domestic financing, high vaccine prices, and gaps in immunization system readiness. This article highlights the need to strengthen governance and sustainable financing mechanisms, optimize resource use, and leverage targeted technical support from global partners to accelerate equitable access to life-saving vaccines and advance the Immunization Agenda 2030.
